Gramaglia Carla, Gambaro Eleonora, Zeppegno Patrizia
Institute of Psychiatry, Università degli Studi del Piemonte Orientale, Novara, Italy.
S.C. Psichiatria, Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy.
Front Psychiatry. 2020 Feb 14;10:991. doi: 10.3389/fpsyt.2019.00991. eCollection 2019.
Alexithymia is of great interest as an outcome predictor of recovery from anorexia nervosa, since it may interfere with both treatment compliance and patients' ability to benefit from the adopted interventions. For this reason, in the last years new treatment approaches targeting emotion identification, expression, and regulation have been applied and tested. Using the PRISMA methodology, we performed a scoping review of the literature about treatment outcome in anorexia nervosa, in terms of changes in alexithymia as assessed by its most commonly used self-report measure, the Toronto Alexithymia Scale (TAS). The Medline and Scopus databases were searched, and articles were included if matching the following criteria: dealing with patients affected by anorexia nervosa, without limits of age; involving the application of any kind of targeted therapy or treatment; assessing alexithymia and the effect of a treatment intervention on alexithymia, using the TAS. Ten studies were eventually included; overall, according to the selected studies, alexithymia levels often remain high even after specific treatment. Further research aimed at a deeper understanding of the actual impact of alexithymia on the outcome of anorexia, as well as exploring alternative treatment strategies for alexithymia in eating disorders (EDs), are warranted.
述情障碍作为神经性厌食症康复的结果预测指标备受关注，因为它可能会干扰治疗依从性以及患者从所采用干预措施中获益的能力。因此，在过去几年中，针对情绪识别、表达和调节的新治疗方法已得到应用和测试。我们采用PRISMA方法，对有关神经性厌食症治疗结果的文献进行了范围综述，内容涉及通过最常用的自我报告量表——多伦多述情障碍量表（TAS）评估的述情障碍变化情况。我们检索了Medline和Scopus数据库，符合以下标准的文章被纳入：涉及受神经性厌食症影响的患者，无年龄限制；涉及任何类型的靶向治疗或疗法的应用；使用TAS评估述情障碍以及治疗干预对述情障碍的影响。最终纳入了10项研究；总体而言，根据所选研究，即使经过特定治疗，述情障碍水平通常仍居高不下。有必要进行进一步研究，以更深入地了解述情障碍对神经性厌食症结局的实际影响，以及探索饮食失调（ED）中述情障碍的替代治疗策略。
